South Korea Ambulatory Infusion Centers Market Size, Share, Growth, and Industry Analysis, By Therapy Type (Anti-infective Therapy, Hydration Therapy, Chemotherapy, Immunoglobulin Therapy), By Application (Oncology, Autoimmune DisordersRheumatoid ArthritisMultiple SclerosisCrohn€™s DiseasePsoriasis, Neurological Disorders, Infectious Diseases) and Forecast, 2026-2034

South Korea Ambulatory Infusion Centers Market Trends

Shift Toward Outpatient, Biologic and Digitally Supported Infusion Delivery

South Korea's high outpatient utilization supports decentralized treatment models. HIRA-linked reporting indicated 17.9 outpatient visits per person in 2024, about 3 times the OECD-level comparison and only 0.6% below the prior year. Meanwhile, Samsung Biologics' 180,000-L Plant 5 incorporates digital twins, AI, automation and autonomous logistics, illustrating the technology intensity developing around biologic production and downstream administration.

Treatment convenience is also shifting through IV-to-SC and ready-to-administer formulations. Celltrion obtained Korean authorization for additional AVTOZMA SC and 80mg/4ml IV presentations in February 2025, while its later Remsima IV liquid formulation reduced preparation time by 51% and preparation costs by 20% in supporting studies. These changes increase operational flexibility for high-throughput infusion settings.

South Korea Ambulatory Infusion Centers Market Drivers

High Outpatient Utilization and Expanding Chronic-Disease Treatment

Demand is reinforced by population ageing, repeated biologic administration and South Korea's intensive outpatient-care pattern. People aged 65+ crossed approximately 10 million and 20% of the population around the country's transition to a super-aged society, while annual outpatient utilization reached 17.9 visits per capita in 2024. National insurance covers diagnosis, treatment, medication, surgery and outpatient services, with stated patient cost-sharing of 30% at clinics, 40% at hospitals and 60% at tertiary hospitals.

South Korea Ambulatory Infusion Centers Market Restraints

Workforce Constraints and Hospital-Centric Care Pathways

Capacity expansion faces staffing and geographic constraints. More than 12,000 trainee doctors participated in the 2024 dispute, while government plans sought up to 10,000 additional physicians by 2035. About 4% of approximately 36,000 private clinics notified authorities of participation in a June 2024 walkout, illustrating operational exposure to workforce disruption. Rural and provincial physician shortages can further concentrate complex infusion care in metropolitan institutions.

South Korea Ambulatory Infusion Centers Market Opportunities

Expansion of Home-Linked and Alternative-Site Infusion Models

Home-linked ambulatory delivery presents an adjacent opportunity. South Korean regulations explicitly permit home nursing activities including medication administration and injections, while the Ministry of Health and Welfare continued long-term-care home-medical-center pilots in 2025. NHIS population data show approximately 36 million employee-insured people, 15 million self-employed insured people and 1.5 million Medical Aid beneficiaries, creating a broad reimbursement-connected patient base for appropriately covered services.

Challenges in South Korea Ambulatory Infusion Centers Market

Reimbursement Complexity and Care-Site Economics

Economics vary materially by treatment setting. NHIS states outpatient cost-sharing can reach 60% at tertiary hospitals versus 50% or 45% at general hospitals depending on administrative area, 40% at hospitals and 30% at clinics. At the same time, the government announced healthcare-system reform investment exceeding KRW 10 trillion amid concerns regarding specialty and regional reimbursement disparities, creating both pricing pressure and incentives to optimize infusion location.

South Korea Ambulatory Infusion Centers Market Segmentation

The market is segmented by therapy type, application, end-user and payor. Anti-infective therapy represents approximately 33.16% of therapy revenue in 2026, while autoimmune disorders represent approximately 29.16% of application revenue.

By Therapy Type

Anti-infective therapy is the largest category, increasing from USD 203.26 million in 2025 to USD 226.68 million in 2026 and USD 542.28 million by 2034 at an 11.52% CAGR. Its 2026 contribution is approximately 33.16%, ahead of hydration therapy and chemotherapy.

Hydration therapy is the fastest-growing therapy category at an 11.65% CAGR, advancing from USD 124.15 million in 2026 to USD 299.80 million in 2034. Immunoglobulin therapy follows at 11.64%, biological therapy at 11.48%, enteral/parenteral nutrition at 11.26%, chemotherapy at 11.16%, and other therapies at 11.01%.

By Application

Autoimmune disorders lead applications at USD 199.27 million in 2026 and USD 470.59 million by 2034, registering an 11.34% CAGR. They account for approximately 29.16% of the 2026 application total, ahead of oncology at USD 191.68 million.

Infectious diseases and gastrointestinal disorders are the fastest-growing applications, each at 11.59% CAGR. Oncology records 11.58%, other applications 11.44%, neurological disorders 11.28%, and immune deficiencies 10.90%. Autoimmune treatment includes rheumatoid arthritis, multiple sclerosis, Crohn's disease and psoriasis.

By End-User

Hospital-affiliated centers benefit from established pharmacy, oncology and emergency infrastructure and remain structurally important for complex infusions. The end-user framework additionally covers physician-office infusion centers, standalone centers and home-infusion providers with ambulatory setups. No end-user revenue split was supplied; therefore, numerical market shares are not inferred.

Alternative-site expansion is supported by home-care rules permitting medication and injection services under qualified nursing arrangements. South Korea's insurance architecture covers roughly 36 million employee-insured people and 15 million self-employed insured people, providing a large reimbursed-care population.

By Payor Type

South Korea differs from the U.S.-style Medicare/Medicaid terminology included in the requested segmentation. The country's core system is compulsory National Health Insurance, operated through a single insurer, with Medical Aid covering approximately 1.5 million people as of the cited population data.

For analytical consistency, commercial/private insurance and self-pay can be tracked separately, while Medicare and Medicaid should be interpreted cautiously because they are not Korean statutory programs. Patient outpatient cost-sharing ranges from 30% at clinics to 60% at tertiary hospitals under NHIS benefit rules.

South Korea Ambulatory Infusion Centers Market Counties Outlook

Seoul Capital Area

Seoul, Incheon and Gyeonggi form the country's principal concentration of tertiary medicine, biotechnology and specialty treatment capacity. Nationally, the therapy-based benchmark is USD 683.63 million in 2026, while anti-infective therapy contributes 33.16%. Incheon additionally hosts Samsung Biologics' manufacturing complex, whose capacity reached 784,000 L following Plant 5. No verified Seoul-specific revenue percentage was supplied.

Chungcheong, Yeongnam, Honam and Jeju

Provincial markets participate through general hospitals, clinics and regional medical institutions, although physician availability remains less concentrated than in metropolitan areas. National application benchmarks show autoimmune disorders at 29.16% and oncology at 28.05% in 2026. Regional revenue percentages and infusion-production volumes were not supplied and are not estimated, preventing artificial allocation of the USD 683.63 million national total.

South Korea Ambulatory Infusion Centers Market Counties Outlook

Seoul Capital Area

Seoul, Incheon and Gyeonggi form the country's principal concentration of tertiary medicine, biotechnology and specialty treatment capacity. Nationally, the therapy-based benchmark is USD 683.63 million in 2026, while anti-infective therapy contributes 33.16%. Incheon additionally hosts Samsung Biologics' manufacturing complex, whose capacity reached 784,000 L following Plant 5. No verified Seoul-specific revenue percentage was supplied.

Chungcheong, Yeongnam, Honam and Jeju

Provincial markets participate through general hospitals, clinics and regional medical institutions, although physician availability remains less concentrated than in metropolitan areas. National application benchmarks show autoimmune disorders at 29.16% and oncology at 28.05% in 2026. Regional revenue percentages and infusion-production volumes were not supplied and are not estimated, preventing artificial allocation of the USD 683.63 million national total.

Top players in South Korea Ambulatory Infusion Centers Market

• Samsung Medical Center
• Seoul National University Hospital
• Asan Medical Center
• Severance Hospital
• Seoul St. Mary's Hospital
• National Cancer Center Korea
• Samsung Biologics
• Samsung Bioepis
• Celltrion
• GC Biopharma
• SK bioscience
• LOTTE Biologics

Top Two Companies

• Samsung Medical Center

A major tertiary-care institution positioned around oncology, immune-mediated disease and other high-acuity specialties requiring recurring outpatient administration. A verified company-specific percentage of South Korean ambulatory infusion-center revenue is not publicly disclosed, so no unsupported share is assigned. Its positioning is strengthened by Korea's high outpatient utilization of 17.9 visits per capita and the wider Samsung biotechnology ecosystem, including Samsung Biologics' 784,000-L capacity after commissioning its 180,000-L Plant 5.

• Seoul National University Hospital

SNUH represents another major tertiary provider positioned for complex oncology, immunology and specialty-drug administration. A defensible national operator revenue percentage is likewise unavailable and is therefore not fabricated. The institutional environment benefits from near-universal statutory insurance architecture, while tertiary-hospital outpatient cost-sharing can reach 60% under NHIS rules. These reimbursement economics create incentives to shift clinically appropriate recurring infusions toward lower-cost ambulatory environments.

Recent Developments in South Korea Ambulatory Infusion Centers Market

• 2025:Samsung Biologics prepared 180,000-L Plant 5 for operation, expanding total capacity to 784,000 L and incorporating AI, digital-twin and automation technologies.
• 2025:Celltrion secured Korean approval for AVTOZMA's SC formulation and an additional 80mg/4ml IV presentation, complementing 200mg/10ml and 400mg/20ml IV formats.
• 2025:LOTTE Biologics reported development of Songdo Bio Campus Plant 1 following a USD 1 billion investment, targeting commercial production from 2027.
• 2025:The Ministry of Health and Welfare selected a second group of participating institutions for its cancer-patient home-medical-care pilot, extending experimentation with decentralized care delivery.
• 2025:Celltrion's Remsima IV liquid formulation received European authorization; supporting data indicated 51% shorter preparation time and 20% lower preparation costs, demonstrating workflow innovations relevant to infusion operations.

Research Methodology

The analysis uses the supplied 2025, 2026 and 2034 numerical tables as the mandatory primary source for revenue, segment contribution and CAGR calculations. Therapy-based totals are used for headline valuation because that table reports USD 613.33 million in 2025, USD 683.63 million in 2026 and USD 1,629.03 million in 2034. The separate application table reports USD 613.32 million, USD 683.40 million and USD 1,624.02 million respectively; these differences are retained rather than normalized. Secondary evidence was limited to official Korean government, NHIS, MFDS, corporate and other cited sources for healthcare infrastructure, regulation, reimbursement and industry developments. Unsupported regional and company revenue percentages were deliberately excluded.